The Investment Management Team
The investment management team has a breadth of experience and knowledge across both public and private investments in the biotechnology and healthcare sectors.
The majority of the Trust's investments made are in public markets and are managed by Ailsa Craig and Marek Poszepczynski. Private or venture capital investments are made via a venture fund, currently SV Fund VI, under the guidance of the SV core Biotech team co-led by Kate Bingham and Houman Ashrafian.
- Ailsa Craig Lead Investment Manager
- Marek Poszepczynski Lead Investment Manager
- Kate Bingham Investment Manager
- Houman Ashrafian Investment Manager
- Lucy Costa Duarte Head of Investor Relations
- James Costine Finance Partner
- Hari Sabharwal Fund Controller
- Jonathan Mott Compliance Officer
- Mariann Metsis Executive Assistant
Board of Directors
The Board determines and monitors the Trust's investment objective and policy, and considers its future strategic direction: being collectively responsible for the long-term success of the Trust.
They meet formally five times a year, but also meet informally on other occasions, as required. As is appropriate, they have delegated various functions to other parties, the performance of which are regularly reviewed.
The Alternative Investment Fund Manager
SV Health Managers is a specialist healthcare fund manager investing across multiple stages and sectors. SV manages healthcare private equity and venture funds as well as, in the public equities space, International Biotechnology Trust. International Biotechnology Trust benefits from an investment in one of SV’s venture funds, as well as being able to draw on the extensive expertise of SV’s specialist investment team across all four of its focus areas. These focus areas are Biotechnology, Dementia, Healthcare Growth and Medtech.
International Biotechnology Trust Details
6th May 1994
Late October / Early November
10% of quoted portfolio NBI (£) outperformance plus a 0.5% hurdle
20% of net gains made from unquoted investments
See page 26 of the Annual Report
At AGM in 2023; every two years
4% of NAV p.a. bi-annually - please see dividend policy for more details
Dividend Payment Dates
January and August each year
Ex Dividend Dates
December and July each year
Next Ex Dividend Date
London Stock Exchange
Issued Share Capital at 31 December 2022
40,764,829 (excluding 618,988 shares in treasury)